Dopamine Agonist and Sedative Combination for Sleep Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for insomnia, such as benzodiazepines and non-benzodiazepine sedative-hypnotics, often cause side effects like hangover effects, tolerance, rebound insomnia, and impaired next-day functioning, particularly in the elderly, and there is a need for sedative-dopamine agonist compositions that can induce and maintain sleep effectively as single-dose nocturnal formulations.
Innovation Solution
Pharmaceutical compositions comprising a dopamine agonist, specifically optically pure (S)-didesmethylsibutramine, combined with a sedative agent like optically pure (S)-zopiclone or (S)-N-desmethylzopiclone, which are administered together to treat insomnia, restless-leg syndrome, and periodic-limb-movement disorder, providing a therapeutic effect that improves sleep quality without the adverse effects of traditional sedatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional sedative-hypnotics (benzodiazepines, non-benzodiazepine compounds) are used to treat insomnia, then sleep induction is achieved, but side effects such as hangover effects, tolerance, rebound insomnia, and impaired next-day functioning occur
Solution Approach 1:
The patent segments the sleep treatment into two distinct components: a short-acting sedative-hypnotic (half-life 1-6 hours) for sleep induction and a dopamine agonist for sleep maintenance. This segmentation allows each component to perform its specific function optimally while minimizing overlapping side effects, particularly hangover effects and next-day impairment.
Solution Approach 2:
The patent combines two different pharmacological mechanisms (sedative-hypnotic and dopamine agonist) into a single therapeutic regimen. The sedative-hypnotic induces sleep rapidly, while the dopamine agonist maintains sleep by addressing underlying dopaminergic deficits, creating a synergistic effect that improves overall sleep quality without the cumulative side effects of traditional single-agent therapies.
2Duration of action of stationary object
If long-acting sedative compounds are used to maintain sleep throughout the night, then sleep maintenance is improved, but unwanted hangover effects and next-day impairment increase
Solution Approach 1:
The patent divides the sleep maintenance function between a short-acting sedative-hypnotic that clears from the system by morning and a dopamine agonist that provides sustained therapeutic effect without sedative hangover effects. This segmentation enables sleep maintenance throughout the night while ensuring the sedative component does not cause next-day impairment.
Solution Approach 2:
The patent changes the pharmacokinetic parameter of the sedative-hypnotic component to have a short half-life (1-6 hours), ensuring it is eliminated from the system before morning. Simultaneously, it introduces a dopamine agonist with longer duration of action to maintain sleep coverage, thereby achieving sleep maintenance without prolonged sedative exposure that causes hangover effects.
3Duration of action of stationary object
If high plasma concentration of sedative compound is maintained constantly throughout the night, then sleep maintenance is improved, but overall dosage increases and unwanted effects are exacerbated
Solution Approach 1:
The patent segments the therapeutic function into sleep induction (sedative-hypnotic) and sleep maintenance (dopamine agonist). The sedative-hypnotic is administered at low doses that achieve rapid sleep induction and are then cleared from the system, while the dopamine agonist maintains sleep at lower overall dosages compared to continuous high-dose sedative administration.
Solution Approach 2:
The patent employs periodic action by administering a short-acting sedative-hypnotic that produces a temporary high plasma concentration for sleep induction, followed by a decline to low levels by morning. The dopamine agonist provides sustained but lower-level therapeutic effect, creating a periodic pharmacokinetic profile that maintains sleep without requiring constant high dosing.
Data Source
AI summary
The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone.